Results 81 to 90 of about 26,161 (209)

Advances in FGF/FGFR Signaling: Implications for Disease and Therapy

MedComm, Volume 7, Issue 9, September 2026.
The FGF/FGFR signaling is indispensable for the maintenance of physiological homeostasis and governs multiple biological processes, including embryonic development, bone metabolism, angiogenesis, and neurogenesis, whereas aberrant hyperactivation of this pathway drives the progression of malignancies and autoimmune disorders, including inflammatory ...
Miaoyu Song, Xi Liu, Yang Xiao, Yongsheng Li, Huakan Zhao   +4 more
wiley   +1 more source

Abscopal Effect in Radiation Therapy: The Immune Mechanisms and Clinical Advances

MedComm, Volume 7, Issue 9, September 2026.
The schematic outlines the key events of the abscopal effect. (Ignition) Local radiotherapy (RT) induces the release of immunogenic signals from the tumor, leading to dendritic cell (DC) activation. (Orchestration) In the tumor‐draining lymph node (TDLN), DCs prime naive T cells into cytotoxic T lymphocytes (CTLs), a process modulated by regulatory T ...
Yihong Dong, Moran Chen, Xupeng Hou, Xiaoya Tang, Xiaoli Yu, Jing Liu   +5 more
wiley   +1 more source

ADCC: the rock band led by therapeutic antibodies, tumor and immune cells

Frontiers in Immunology
Antibody-dependent cellular cytotoxicity (ADCC) is a critical mechanism by which therapeutic antibodies leverage the immune system to target and eliminate cancer cells. The key agents of ADCC are natural killer (NK) cells, specifically targeting antibody-
Roos Vincken, Roos Vincken, Uxue Armendáriz-Martínez, Ana Ruiz-Sáenz, Ana Ruiz-Sáenz   +4 more
doaj   +1 more source

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

SSR4 Sustains Tertiary Lymphoid Structures by Regulation Quality Control of N‐linked Glycosylation During B‐cell Differentiation Into Plasmacyte in Colorectal Cancer

Advanced Science, Volume 13, Issue 46, 17 August 2026.
SSR4, a TRAP component induced in B cells, governs BAFFR N‐glycosylation via DDOST to sustain NF‐κB signaling, B‐cell differentiation, and TLS maturation. Its loss impairs anti‐tumor immunity, while overexpression improves antibody glycosylation and ADCC, revealing a critical regulator for cancer immunotherapy.
Wei Zhao, Youcai Zhao, Haiyang Li, Bowen Yang, Siyan Lu, Xueting Fu, Caixia Zhang, Yirong Chen, Xiaofeng Bian, Xinghua Ma, Xiaobing Yang, Bin Wang, Yuan Fang, Lulu Yang, Yelin Zhao, Shuli Zhao   +15 more
wiley   +1 more source

Epidemiological Characterizations and Diagnostic Strategies Variation in Parotid Gland Tumors (2010–2024): Observations Based on 2133 Cases

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Objective To analyze epidemiological trends and diagnostic approaches for parotid gland tumors (PGTs) from 2010 to 2024 and predict future trends. Methods A total of 2591 surgically and pathologically confirmed PGTs were reviewed. After excluding metastatic tumors, non‐neoplastic lesions, hematolymphoid tumors, and other non‐epithelial lesions,
Linwen Huang, Jiawei Pan, Lu Yang, Zhenyu Xu, Yunjun Yang, Weijun Huang, Zhifeng Xu   +6 more
wiley   +1 more source

Drug Resistance in Multiple Myeloma: Tumor‐Intrinsic Mechanisms and the Bone Marrow Microenvironment

Cell Biochemistry and Function, Volume 44, Issue 8, August 2026.
ABSTRACT Multiple myeloma (MM) is a malignant plasma cell disorder, and despite substantial improvements in prognosis achieved through chemotherapy, immunotherapy, and autologous stem cell transplantation, most patients ultimately develop relapsed or refractory disease. Drug resistance (DR) is increasingly recognized as a dynamically evolving ecosystem
Yixuan Chen, Wenming Huang, Mingxuan Tang, Xiaotao Wang   +3 more
wiley   +1 more source

Manufacturing and clinical applications of non‐CAR‐T immune effector cells

Transfusion, EarlyView.
Thane Kubik, Theodros Mamo, David H. McKenna   +2 more
wiley   +1 more source

Integrin α5β1 in pancreatic ductal adenocarcinoma: Tumour‒stroma crosstalk, hypoxia and therapeutic targeting

Clinical and Translational Medicine, Volume 16, Issue 8, August 2026.
ITGA5/integrin α5β1 promotes PDAC progression by integrating fibronectin‐dependent adhesion, hypoxia‐associated ECM remodelling, pancreatic stellate cell/cancer‐associated fibroblast activation, desmoplasia and tumour‒stroma crosstalk. These processes contribute to impaired drug delivery and therapeutic resistance.
Chenzhe Ma, Yingying Wang, Yumin Li
wiley   +1 more source

SLC7A5 promotes colorectal cancer liver metastasis by reprogramming tryptophan metabolism through the Kyn/XANA‒AhR axis and reshaping the immune microenvironment

Clinical and Translational Medicine, Volume 16, Issue 8, August 2026.
SLC7A5‒Kyn/XANA signalling activates AhR to drive EMT and metastatsis. SLC7A5 knockdown enhances macrophage antigen presentation and reverses CD8+ T‐cell exhaustion. SLC7A5 knockdown induces antigen‐driven and IgG‐secreting B‐cell clonal expansion. Combination of SLC7A5 inhibition and anti‐PD‐1 therapy offers clinical targeting.
Yaohao Luo, Lei Li, Shanbao Li, Xinshuai Wang, Zeping He, Fangbin Song, Jun Qin, Jinyan Zhang, Junming Xu   +8 more
wiley   +1 more source